Evidence map›Paper›PMID 39056624›Full record

ArticleBiosensors2024

Enhanced Point-of-Care SARS-CoV-2 Detection: Integrating RT-LAMP with Microscanning.

Minkyeong Choi, Eunji Lee, Seoyeon Park, Chae-Seung Lim, Woong-Sik Jang

Abstract read
In one paragraph

Article in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Simultaneous and sensitive detection ofFrontiers in bioengineering and biotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Minkyeong ChoiBK21 Graduate Program, Department of Biomedical Sciences, College of Medicine, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.ORCID 0009-0004-6948-1233
Eunji LeeDepartment of Laboratory Medicine, College of Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea.ORCID 0009-0004-8916-7604
Seoyeon ParkDepartment of Laboratory Medicine, College of Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea.ORCID 0009-0007-7937-3086
Chae-Seung LimBK21 Graduate Program, Department of Biomedical Sciences, College of Medicine, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.ORCID 0000-0002-7765-0840
Woong-Sik JangDepartment of Laboratory Medicine, College of Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea.ORCID 0000-0002-2910-0537

Funding

the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education 2022R1I1A1A01063976the Korea Health Technology R&D Project, through the Korea Health Industry Development In-stitute HR20C0021the National Research Foundation of Korea (NRF), funded by the Korean Government, MSIP RS- 2023-00207833
6 · The paper itself

Abstract

The COVID-19 pandemic has highlighted the urgent need for rapid and accurate diagnostic methods for various infectious diseases, including SARS-CoV-2. Traditional RT-PCR methods, while highly sensitive and specific, require complex equipment and skilled personnel. In response, we developed an integrated RT-LAMP-MS assay, which combines rapid reverse transcription loop-mediated isothermal amplification (RT-LAMP) with microscanning (MS) technology for detecting SARS-CoV-2. The assay uses magnesium pyrophosphate formed during LAMP amplification as a visual marker, allowing direct observation via microscopy without the need for additional chemical indicators or probes. For the SARS-CoV-2/IC RT-LAMP-MS assay, the sample-LAMP reagent mixture was added to a microchip with SARS-CoV-2 primers and internal controls, then incubated at 62 °C for 30 min in a heat block, followed by amplification analysis using a microscanner. In clinical tests, the RT-LAMP-MS assay showed 99% sensitivity and 100% specificity, which is identical to the RT-LAMP results and comparable to the commercial Allplex

Indexed as

COVID-19Molecular Diagnostic TechniquesNucleic Acid Amplification TechniquesPoint-of-Care SystemsSARS-CoV-2COVID-19 Nucleic Acid TestingHumansRNA, ViralSensitivity and SpecificityRNA, Viralmagnesium pyrophosphatepoint-of-care testingRT-LAMPSARS-CoV-2visual detection

Identifiers

PMID39056624
PMCPMC11274610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.